Fibromyalgia is a condition that causes lasting and debilitating muscle pain and fatigue. In the recent years, cases of road traffic injuries have been rising at an alarming rate, which further leads to the rising prevalence of fibromyalgia as road traffic accidents are likely to develop widespread chronic pain. Psychiatric disorders are increasingly prevalent in case of fibromyalgia, and post-traumatic stress disorders are also seen with the increasing occurrence rate. Screening for post-traumatic stress disorder symptoms is also an essential part of the assessment process in patients suffering from fibromyalgia.
It is noted that the rising occurrences of traumatic stress and road accidents is the key factor driving the fibromyalgia treatment market. According to a study published in the Pain Research and Management Journal, in 2014, it was found that physical trauma is followed by the fibromyalgia syndrome. In the study, conducted with a specific cohort of individuals involved in motor vehicle collisions, it was found that 8% of individuals developed widespread chronic pain. Fibromyalgia is characterized by widespread chronic pain. The study has also demonstrated the incidence rate of fibromyalgia in the survivors of a train crash in Israel which was 15%.
Other factors, such as increasing cases of rheumatic diseases, growing awareness among the population, rising geriatric population, unmet medical needs in the fibromyalgia treatment, and rising popularity of Chinese treatment options are also promoting the growth of the market. Fibromyalgia is considered as a confounding factor for the diagnosis and the assessment of the rheumatic disease activity.
Despite these drivers, there are some issues associated with the fibromyalgia treatment market. Lack of infrastructure in middle- and low-income countries and difficult diagnosis may hamper the growth of the market. Irritable Bowel Syndrome (IBS) is also found to be highly associated with fibromyalgia. According to the study published in the Medicine Journal in 2015, fibromyalgia was associated with a 1.54-fold increased risk for the irritable bowel syndrome. In Taiwan, the incidence rate of IBS is found to be around 10 to 20%, whereas the incidence rate of fibromyalgia in Taiwan's general population is around 2 to 4%.
It is estimated that the Fibromyalgia Treatment Market Is Expected To Grow at a CAGR Of 17.5% During The Forecast Period Of 2017 To 2023.
Segmentation
The fibromyalgia treatment market is segmented on the basis of treatment, diagnosis, and end-user.
On the basis of treatment, the market is segmented into symptomatic treatment and targeted treatment.
On the basis of diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.
On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Key Players
Some of the key players in the fibromyalgia treatment market are Pfizer, GlaxoSmithKline, AstraZeneca, F. Hoffmann-La Roche AG, Astellas Pharma, Johnson & Johnson Services, Inc., SANOFI, Eli Lilly and Company, Bayer AG, ALLERGAN, Boehringer Ingelheim, AbbVie, Cephalon, Inc., Sunovion Pharms Inc, Jazz Pharmaceuticals, Vertical Pharmaceuticals, ABBOTT, NOVARTIS, and others.
Request Customization
Get a Sample
Get a Sample
Request Customization